Bioxytran's ProLectin-M Achieves 100% Viral Clearance in Phase 2 Trial
核心洞察
Bioxytran (搜索) reported complete elimination of viral load in 100% of treated patients by day 7 in a Phase 2 trial of ProLectin-M versus placebo (p=0.001).
The randomized, double-blind, placebo-controlled study enrolled 38 subjects with acute viral infection, all completing the seven-day treatment period.
ProLectin-M demonstrated rapid viral clearance with 16 of 38 subjects achieving non-detection by day 5 and no viral rebounds during 14-day follow-up.
Bioxytran (搜索), Inc. has announced positive results from its Phase 2 randomized, double-blind, placebo-controlled trial of ProLectin-M, demonstrating complete viral clearance in all treated patients with laboratory-confirmed acute viral infection. The study achieved its primary endpoint with 100% of treated subjects showing complete elimination of viral load by day 7, compared to placebo (p=0.001).
Study Design and Population
The dose-optimization trial enrolled 38 subjects, all of whom completed the study protocol. Participants were randomized to receive one of three ProLectin-M dose levels or matching placebo, administered orally over a seven-day treatment period. Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs collected at predefined timepoints, with viral clearance defined as non-detection of viral RNA below established PCR thresholds.
The current trial built upon findings from Bioxytran (搜索)'s earlier Phase 2 study, which demonstrated statistically significant reductions in viral load by day 7, early clearance as soon as day 3, and no observed viral rebounds during a 14-day post-treatment observation period. The latest study refined dose selection to four tablets per day and evaluated the reproducibility of rapid viral clearance using the same core virologic assessment methodology.
Rapid Viral Clearance Results
Following database lock and unblinding, the treatment demonstrated remarkable efficacy across multiple timepoints. By day 3, one of 38 subjects demonstrated non-detection of viral shedding. This number increased to 16 of 38 subjects by day 5, with complete clearance achieved in all 38 subjects by day 7.
Importantly, no viral rebounds were observed in the treated population during the 14-day post-treatment observation period, indicating sustained viral suppression beyond the active treatment phase.
"The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by day 7," said Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran (搜索). "The results demonstrate that viral clearance occurred more rapidly than anticipated, with a significant proportion of treated subjects achieving viral non-detection by day 3 and complete clearance by day 7."
Novel Mechanism of Action
ProLectin-M distinguishes itself through its unique approach to antiviral therapy. Rather than targeting viral replication inside cells, the galectin (搜索) antagonist is designed to interfere with viral entry at the cell surface. This extracellular mechanism may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy.
"What continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action," noted Dr. Platt. "Rather than targeting viral replication inside the cell, our galectin (搜索) antagonist is designed to interfere with viral entry at the cell surface. This extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy."
The company believes these results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology.
Development Path Forward
Based on these positive results, Bioxytran (搜索) plans to advance regulatory discussions to support late-stage clinical development. The company is also evaluating ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.
The clinical-stage biotechnology company is developing novel carbohydrate-based therapeutics targeting significant unmet medical needs in virology and other disease areas, with ProLectin-M as its lead program being developed as a potential broad-spectrum antiviral therapeutic.